The poster will summarize the clinical and pathological data of the Bria-IMT monotherapy study and Phase I/IIa clinical study of Bria-IMT in combination with immune checkpoint inhibitors including pembrolizumab (KEYTRUDA; manufactured by
The presentation will be posted on https://briacell.com/novel-technology/scientific-publications/.
The details on the poster presentations are as follows:
Abstract Number: 1313
Presentation Title: Response to a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer correlates with tumor grade
Session Date:
Program Number: PS17-20
Session Title: Poster Session 17
The abstracts for these presentations will be available online on the SABCS website at https://www.sabcs.org.
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
For additional information on BriaCell, please visit: https://briacell.com/.
About SABCS
Since its inception in 1977, San Antonio Breast Cancer Symposium (SABCS) has grown to a program that covers the latest research on the experimental biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease. The Symposium is attended by a large international audience of researchers, health professionals, physicians, oncologists, and those with a special interest in breast cancer from over 90 countries.
To complement the clinical focus of the annual SABCS,
For additional information on 2020 SABCS, please visit: https://www.sabcs.org.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains 'forward-looking information' within the meaning of the applicable Canadian securities legislation (also known as 'forward-looking statements') which are subject to known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company's public filings available at www.sedar.com.
These forward-looking statements include, but are not limited to, BriaCell's plans, objectives, expectations and intentions. Such forward-looking statements reflect BriaCell's current beliefs and are based on information currently available to management. Although the forward-looking statements contained in this news release are based upon what BriaCell believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither
Contact:
President & CEO
Phone: 1-888-485-6340
Manager, Corporate Development
Email: farrah@BriaCell.com
Phone: 1-888-485-6340
(C) 2020 Electronic News Publishing, source